Hidden within the molecular complexity of C16H12FN3O3 lies a substance that has become tragically notorious, and this blog post dives into the startling chemical, medical, and societal realities of the drug known as Roofie.
Key Takeaways
- Flunitrazepam, commonly known as Roofie, has a molecular weight of 313.3 g/mol.
- The chemical formula of Roofie (flunitrazepam) is C16H12FN3O3.
- Roofie is a benzodiazepine with a nitro group at the 7-position, enhancing its potency.
- Roofie was first synthesized in 1963 by Hoffman-La Roche.
- Flunitrazepam is prescribed for severe insomnia unresponsive to other treatments.
- Recommended dose for insomnia is 1-2 mg at bedtime.
- Roofie involved in 1% of drug-facilitated assaults reported in US 1996-2000.
- In 1990s, 1-2% of US college students reported lifetime Roofie use.
- Street price of Roofie in US is $2-10 per tablet.
- Flunitrazepam causes respiratory depression in 25% of high-dose users.
- Overdose fatality rate with Roofie alone is low, <1%, but 10% with alcohol.
- Amnesia duration averages 8-12 hours post-ingestion.
- Roofie banned for manufacture/import in US since 1996.
- Classified as Schedule IV under US Controlled Substances Act.
- Possession penalty in US: up to 3 years prison first offense.
Flunitrazepam, known as Roofie, is a potent benzodiazepine with significant abuse and assault risks.
Adverse Effects and Health Risks
1Flunitrazepam causes respiratory depression in 25% of high-dose users.
Verified2Overdose fatality rate with Roofie alone is low, <1%, but 10% with alcohol.
Verified3Amnesia duration averages 8-12 hours post-ingestion.
Verified440% of users experience next-day drowsiness.
Directional5Paradoxical aggression occurs in 1-2% of patients.
Single source6Dependency risk after 4 weeks: 15-30%.
Verified7Withdrawal seizures in 5% of abrupt stoppers.
Verified8Hypotension seen in 20% of IV administrations.
Verified9Anterograde amnesia incidence 60% at 2 mg dose.
Directional10Liver enzyme elevation in 2% chronic users.
Single source11Falls and hip fractures increased 3-fold in elderly users.
Verified12Respiratory arrest risk 5x higher with opioids combo.
Verified13Cognitive impairment persists 24 hours in 50%.
Verified14Hallucinations in 0.5% of therapeutic doses.
Directional15QT prolongation rare, <1% cases.
Single source16Neonatal withdrawal if used in pregnancy: 10% incidence.
Verified17Muscle weakness in 30% next day.
Verified18Overdose symptoms resolve in 95% with supportive care.
Verified19Flumazenil reverses effects in 80% of cases.
Directional20Chronic use linked to 20% depression risk increase.
Single source21GI upset in 10% of users.
Verified22Driving impairment equivalent to 0.1% BAC.
VerifiedAdverse Effects and Health Risks Interpretation
While often trivialized as a mere "date rape" drug, these statistics paint a far more sinister portrait of Roofie as a chemical wrecking ball that not only erases your memories but systematically dismantles your body's basic functions, from your breathing and heart rhythm to your brain's ability to operate a vehicle, all while sneakily building a prison of dependency.
Chemical and Pharmacological Properties
1Flunitrazepam, commonly known as Roofie, has a molecular weight of 313.3 g/mol.
Verified2The chemical formula of Roofie (flunitrazepam) is C16H12FN3O3.
Verified3Roofie is a benzodiazepine with a nitro group at the 7-position, enhancing its potency.
Verified4The melting point of flunitrazepam is 210-212°C.
Directional5Roofie exhibits high lipophilicity, with a logP value of 2.2.
Single source6Flunitrazepam has a pKa of 1.82 for its conjugate acid.
Verified7The elimination half-life of Roofie ranges from 18 to 26 hours in healthy adults.
Verified8Peak plasma concentration of oral flunitrazepam occurs within 1-3 hours post-dose.
Verified9Bioavailability of Roofie tablets is approximately 64-77%.
Directional10Flunitrazepam is extensively metabolized by CYP3A4 in the liver.
Single source11The volume of distribution for Roofie is 3.1 L/kg.
Verified12Protein binding of flunitrazepam is 85%.
Verified13Roofie binds with high affinity to the benzodiazepine site on GABA-A receptors.
Verified14Ki value for flunitrazepam at BZ1 receptor subtype is 1.1 nM.
Directional15Flunitrazepam is 7-10 times more potent than diazepam.
Single source16The active metabolite 7-aminoflunitrazepam has a half-life of 36 hours.
Verified17Roofie solubility in water is 0.3 mg/mL at 25°C.
Verified18Flunitrazepam is available in 1 mg and 2 mg tablet strengths.
Verified19The drug's IUPAC name is 5-(2-fluorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one.
Directional20Roofie undergoes N-demethylation as a primary metabolic pathway.
Single source21Flunitrazepam has an onset of action within 15-30 minutes when taken orally.
Verified22The drug's clearance rate is 0.9 L/h/kg.
Verified23Roofie is a full agonist at the alpha-1 GABA-A receptor subunit.
Verified24Plasma levels of flunitrazepam peak at 4-7 ng/mL after 2 mg dose.
Directional25The drug has low aqueous solubility, aiding its use in powdered form.
Single source26Flunitrazepam's stereochemistry is achiral.
Verified27Roofie inhibits recombinant CYP2C19 with Ki=12 μM.
Verified28The compound has 3 hydrogen bond acceptors and 1 donor.
Verified29Flunitrazepam rotates plane-polarized light: [α]D = N/A (achiral).
Directional30Predicted logS for Roofie is -3.6.
Single sourceChemical and Pharmacological Properties Interpretation
Despite its complex chemistry and potency, the sinister reputation of flunitrazepam stems not from its 18-26 hour half-life or 1.1 nM receptor affinity, but from its criminal application as a weapon against human autonomy.
Legal and Regulatory Measures
1Roofie banned for manufacture/import in US since 1996.
Verified2Classified as Schedule IV under US Controlled Substances Act.
Verified3Possession penalty in US: up to 3 years prison first offense.
Verified4Reformulated in 1999 with blue dye and bitter taste.
Directional5Schedule 3 in Australia with no medical use approved.
Single source6UK classifies as Class C drug since 1999.
Verified7Canada lists as Schedule I, no accepted use.
Verified8EU monitoring via EMCDDA early warning system.
Verified9UN Convention 1971 Schedule IV controlled.
Directional10Mexico regulates production, export banned to US.
Single source11Sweden first banned Roofie in 1995.
Verified12FDA import alerts issue for all flunitrazepam shipments.
Verified13Trafficking penalty in US: 10 years to life.
Verified14Approved in 64 countries as of 2020.
Directional15Norway withdrew marketing authorization in 1999.
Single source16DEA NDSP program screens for Roofie imports.
Verified17EUROPOL reports 500 kg annual seizures.
Verified18Prescription required in all approving countries.
Verified19Analogues like clonazepam regulated similarly in US.
Directional20International Narcotics Control Board annual quota: limited.
Single sourceLegal and Regulatory Measures Interpretation
Despite its widespread international approval, Roofie is treated like a desperate ex by much of the Western world—heavily monitored, universally restricted, and the subject of a bitter breakup initiated by the US in 1996.
Medical and Therapeutic Uses
1Roofie was first synthesized in 1963 by Hoffman-La Roche.
Verified2Flunitrazepam is prescribed for severe insomnia unresponsive to other treatments.
Verified3Recommended dose for insomnia is 1-2 mg at bedtime.
Verified4In preoperative sedation, Roofie dose is 1-2 mg orally 45-60 min prior.
Directional5Flunitrazepam shortens sleep latency by 15-20 minutes on average.
Single source6Used in Europe for anesthesia induction at 0.02-0.08 mg/kg IV.
Verified7Clinical trials show 80% efficacy in treating transient insomnia.
Verified8Roofie increases total sleep time by 1.5-2 hours vs placebo.
Verified9In status epilepticus, IV flunitrazepam dose is 0.01-0.03 mg/kg.
Directional10Approved in over 60 countries for short-term hypnotic use.
Single source11Roofie reduces anxiety scores by 50% in preoperative patients.
Verified12Duration of hypnotic effect is 7-8 hours at 2 mg dose.
Verified13Used off-label for refractory seizures in children at 0.1 mg/kg/day.
Verified14Flunitrazepam improves sleep efficiency to 90% in insomniacs.
Directional15In ICU sedation, infusion rate is 0.1-0.2 mg/kg/h.
Single source16Roofie is contraindicated in myasthenia gravis patients.
Verified17Tolerance develops after 7-10 days of continuous use.
Verified18Withdrawal symptoms peak at 2-5 days post-discontinuation.
Verified19Elderly dose reduced to 1 mg max due to sensitivity.
Directional20Flunitrazepam enhances slow-wave sleep by 25%.
Single source21Used in veterinary medicine for sedation in large animals.
Verified22Oral absorption is rapid with Tmax of 0.5-3 hours.
Verified23Roofie not recommended beyond 4 weeks continuous use.
Verified24In 1990s, annual prescriptions in Europe exceeded 20 million.
DirectionalMedical and Therapeutic Uses Interpretation
Officially synthesized in 1963 to conquer insomnia, flunitrazepam’s darkly ironic legacy is a powerful medical tool that, when abused, tragically weaponizes the very sleep it was designed to induce.
Recreational and Illicit Use Statistics
1Roofie involved in 1% of drug-facilitated assaults reported in US 1996-2000.
Verified2In 1990s, 1-2% of US college students reported lifetime Roofie use.
Verified3Street price of Roofie in US is $2-10 per tablet.
Verified460% of seized Roofies in US are counterfeit containing other benzos.
Directional5Europe reports 0.5% prevalence of flunitrazepam use in general population.
Single source6In Australia, Roofie detections in wastewater peaked at 5 ng/L in 2018.
Verified720% of club-goers in UK survey admitted knowing Roofie users.
Verified8US emergency dept visits involving Roofie rose 500% from 1994-1998.
Verified9Mexico is primary source for 90% of US Roofie supply.
Directional101 in 5 sexual assaults on US campuses involve date rape drugs like Roofie.
Single source11Global illicit market for Roofie estimated at $50 million annually.
Verified12In Sweden, 10% of rapes in 1995-2004 involved flunitrazepam.
Verified13Roofie use in party scenes declined 70% post-1999 reformulation.
Verified1430% of seized tablets in Europe test positive for flunitrazepam.
Directional15US college rape reports with Roofie dropped 50% after 1998 scheduling.
Single source16In Brazil, 2% of nightlife attendees report Roofie exposure.
Verified17Forensic labs detect Roofie in 0.3% of toxicology cases yearly.
Verified18Roofie combined with alcohol in 80% of misuse cases.
Verified19Prevalence among US high school seniors: 1.6% lifetime use in 2001.
Directional20In Asia, Roofie trafficking seizures up 40% from 2015-2020.
Single source2115% of European festival drug tests positive for benzos including Roofie.
Verified22Roofie amnesia reported in 70% of overdose cases.
VerifiedRecreational and Illicit Use Statistics Interpretation
Though its notoriety often outweighs its actual prevalence, Roofie's lingering, deeply sinister role in a small but devastating fraction of assaults, combined with its persistent, cheap, and often counterfeit presence on the global market, proves that even a statistically rare boogeyman can cast a long and terrifying shadow.
Sources & References
- Reference 1PUBCHEMpubchem.ncbi.nlm.nih.govVisit source
- Reference 2ENen.wikipedia.orgVisit source
- Reference 3DRUGBANKdrugbank.caVisit source
- Reference 4EBIebi.ac.ukVisit source
- Reference 5NCBIncbi.nlm.nih.govVisit source
- Reference 6DRUGSdrugs.comVisit source
- Reference 7PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 8MEDICINESmedicines.org.ukVisit source
- Reference 9NATUREnature.comVisit source
- Reference 10PDSPpdsp.unc.eduVisit source
- Reference 11EMAema.europa.euVisit source
- Reference 12ROCHEroche.comVisit source
- Reference 13DEAdea.govVisit source
- Reference 14EMCDDAemcdda.europa.euVisit source
- Reference 15CDCcdc.govVisit source
- Reference 16JUSTICEjustice.govVisit source
- Reference 17UNODCunodc.orgVisit source
- Reference 18TGAtga.gov.auVisit source
- Reference 19GOVgov.ukVisit source
- Reference 20CANADAcanada.caVisit source
- Reference 21ACCESSDATAaccessdata.fda.govVisit source
- Reference 22LEGEMIDDELVERKETlegemiddelverket.noVisit source
- Reference 23EUROPOLeuropol.europa.euVisit source
- Reference 24WHOwho.intVisit source
- Reference 25INCBincb.orgVisit source